Home / Companies / Quarterly Results / GSK Pharma Q1 results: PAT rises 12% to ₹279 cr, income declines marginally

GSK Pharma Q1 results: PAT rises 12% to ₹279 cr, income declines marginally

Total income declined marginally to ₹849 crore for the first quarter as compared with ₹850 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a regulatory filing

The drug firm had reported a net profit of ₹249 crore for the June quarter of the last fiscal.

2 min read Last Updated : Aug 01 2025 | 4:15 PM IST

Listen to This Article

GlaxoSmithKline Pharmaceuticals on Friday said its consolidated net profit increased 12 per cent year-on-year to ₹279 crore for the June quarter.

The drug firm had reported a net profit of ₹249 crore for the June quarter of the last fiscal.

Total income declined marginally to ₹849 crore for the first quarter as compared with ₹850 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a regulatory filing.

"GSK continues to invest in its innovative portfolio and is on track to launch the much-awaited oncology assets, Jemperli and Zejula. By launching these assets in India, GSK is addressing a critical unmet need amid a rising cancer burden and limited access to advanced therapies," GlaxoSmithKline Pharmaceuticals MD Bhushan Akshikar said.

ALSO READ: Adani Power Q1 FY26 result: Profit down 15%; 1:5 stock split announced

The company continues to invest in its innovative portfolio and is on track to launch the much-awaited oncology assets, Jemperli and Zejula, he added.

By launching these assets in India, GSK is addressing a critical unmet need amid a rising cancer burden and limited access to advanced therapies, Akshikar noted.

Jemperli (dostarlimab) is an immuno-oncology treatment for second-line dMMR endometrial cancer and Zejula (niraparib), is a PARP inhibitor indicated for advanced and recurrent ovarian cancer. Shares of the company were trading 8.22 per cent down at ₹2,898.40 apiece on BSE.

ALSO READ: Procter & Gamble Health rallies 10%, hits 4-year high on strong Q1 results

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)